CLDN18.2-targeted antibody-drug conjugate

DRUG CLASS:

CLDN18.2-targeted antibody-drug conjugate

News alerts, weekly reports and conference planners

Related drugs:

No biomarker	Gastroesophageal Junction Adenocarcinoma	No biomarker	Gastroesophageal Junction Adenocarcinoma	AZD0901 Sensitive: B - Late Trials AZD0901 Sensitive : B	AZD0901 Sensitive: B - Late Trials AZD0901 Sensitive : B
No biomarker	Gastric Cancer	No biomarker	Gastric Cancer	AZD0901 Sensitive: B - Late Trials AZD0901 Sensitive : B	AZD0901 Sensitive: B - Late Trials AZD0901 Sensitive : B
CLDN18.2 expression	Gastric Cancer	CLDN18.2 expression	Gastric Cancer	EO-3021 Sensitive: B - Late Trials EO-3021 Sensitive : B	EO-3021 Sensitive: B - Late Trials EO-3021 Sensitive : B
CLDN18.2 positive	Gastric Cancer	CLDN18.2 positive	Gastric Cancer	IBI-343 Sensitive: B - Late Trials IBI-343 Sensitive : B	IBI-343 Sensitive: B - Late Trials IBI-343 Sensitive : B
CLDN18.2 expression	Gastroesophageal Junction Adenocarcinoma	CLDN18.2 expression	Gastroesophageal Junction Adenocarcinoma	EO-3021 Sensitive: B - Late Trials EO-3021 Sensitive : B	EO-3021 Sensitive: B - Late Trials EO-3021 Sensitive : B
CLDN18.2 positive	Gastroesophageal Junction Adenocarcinoma	CLDN18.2 positive	Gastroesophageal Junction Adenocarcinoma	AZD0901 Sensitive: C2 – Inclusion Criteria AZD0901 Sensitive : C2	AZD0901 Sensitive: C2 – Inclusion Criteria AZD0901 Sensitive : C2
CLDN18.2 positive	Gastric Cancer	CLDN18.2 positive	Gastric Cancer	AZD0901 Sensitive: C2 – Inclusion Criteria AZD0901 Sensitive : C2	AZD0901 Sensitive: C2 – Inclusion Criteria AZD0901 Sensitive : C2
CLDN18.2 expression	Pancreatic Cancer	CLDN18.2 expression	Pancreatic Cancer	SOT102 Sensitive: C2 – Inclusion Criteria SOT102 Sensitive : C2	SOT102 Sensitive: C2 – Inclusion Criteria SOT102 Sensitive : C2
CLDN18.2 expression	Gastric Cancer	CLDN18.2 expression	Gastric Cancer	SOT102 Sensitive: C2 – Inclusion Criteria SOT102 Sensitive : C2	SOT102 Sensitive: C2 – Inclusion Criteria SOT102 Sensitive : C2
CLDN18.2 expression	Pancreatic Cancer	CLDN18.2 expression	Pancreatic Cancer	EO-3021 Sensitive: C2 – Inclusion Criteria EO-3021 Sensitive : C2	EO-3021 Sensitive: C2 – Inclusion Criteria EO-3021 Sensitive : C2
CLDN18.2 expression	Solid Tumor	CLDN18.2 expression	Solid Tumor	EO-3021 Sensitive: C2 – Inclusion Criteria EO-3021 Sensitive : C2	EO-3021 Sensitive: C2 – Inclusion Criteria EO-3021 Sensitive : C2
CLDN18.2 expression	Lung Cancer	CLDN18.2 expression	Lung Cancer	EO-3021 Sensitive: C2 – Inclusion Criteria EO-3021 Sensitive : C2	EO-3021 Sensitive: C2 – Inclusion Criteria EO-3021 Sensitive : C2
CLDN18-ARHGAP fusion	Gastric Cancer	CLDN18-ARHGAP fusion	Gastric Cancer	CLDN18.2-targeted antibody-drug conjugate Sensitive: C3 – Early Trials CLDN18.2-targeted antibody-drug conjugate Sensitive : C3	CLDN18.2-targeted antibody-drug conjugate Sensitive: C3 – Early Trials CLDN18.2-targeted antibody-drug conjugate Sensitive : C3
CLDN18.2 positive	Pancreatic Cancer	CLDN18.2 positive	Pancreatic Cancer	CLDN18.2-targeted antibody-drug conjugate Sensitive: D – Preclinical CLDN18.2-targeted antibody-drug conjugate Sensitive : D	CLDN18.2-targeted antibody-drug conjugate Sensitive: D – Preclinical CLDN18.2-targeted antibody-drug conjugate Sensitive : D
CLDN18.2 underexpression	Gastric Cancer	CLDN18.2 underexpression	Gastric Cancer	ATG-022 Sensitive: D – Preclinical ATG-022 Sensitive : D	ATG-022 Sensitive: D – Preclinical ATG-022 Sensitive : D
CLDN18.2 underexpression	Pancreatic Cancer	CLDN18.2 underexpression	Pancreatic Cancer	LM-302 Sensitive: D – Preclinical LM-302 Sensitive : D	LM-302 Sensitive: D – Preclinical LM-302 Sensitive : D
CLDN18.2 overexpression	Pancreatic Cancer	CLDN18.2 overexpression	Pancreatic Cancer	LM-302 Sensitive: D – Preclinical LM-302 Sensitive : D	LM-302 Sensitive: D – Preclinical LM-302 Sensitive : D
CLDN18.2 overexpression	Gastric Cancer	CLDN18.2 overexpression	Gastric Cancer	LM-302 Sensitive: D – Preclinical LM-302 Sensitive : D	LM-302 Sensitive: D – Preclinical LM-302 Sensitive : D
CLDN18.2 expression	Lung Adenocarcinoma	CLDN18.2 expression	Lung Adenocarcinoma	SOT102 Sensitive: D – Preclinical SOT102 Sensitive : D	SOT102 Sensitive: D – Preclinical SOT102 Sensitive : D
CLDN18.2 expression	Colon Cancer	CLDN18.2 expression	Colon Cancer	SOT102 Sensitive: D – Preclinical SOT102 Sensitive : D	SOT102 Sensitive: D – Preclinical SOT102 Sensitive : D
CLDN18.2 expression	Hepatocellular Cancer	CLDN18.2 expression	Hepatocellular Cancer	SOT102 Sensitive: D – Preclinical SOT102 Sensitive : D	SOT102 Sensitive: D – Preclinical SOT102 Sensitive : D
CLDN18.2 expression	Endometrial Cancer	CLDN18.2 expression	Endometrial Cancer	CLDN18.2-targeted antibody-drug conjugate Sensitive: D – Preclinical CLDN18.2-targeted antibody-drug conjugate Sensitive : D	CLDN18.2-targeted antibody-drug conjugate Sensitive: D – Preclinical CLDN18.2-targeted antibody-drug conjugate Sensitive : D
CLDN18.2 expression	Ovarian Cancer	CLDN18.2 expression	Ovarian Cancer	CLDN18.2-targeted antibody-drug conjugate Sensitive: D – Preclinical CLDN18.2-targeted antibody-drug conjugate Sensitive : D	CLDN18.2-targeted antibody-drug conjugate Sensitive: D – Preclinical CLDN18.2-targeted antibody-drug conjugate Sensitive : D

CLDN18.2-targeted antibody-drug conjugate

CLDN18.2-targeted antibody-drug conjugate

Associations(23)

Associations
(23)